Back Home Search

Metastatic / Recurrent

    • Protocols
    • GOG3069

      OPEN TO ACCRUAL

      Ph2 Study of Alpelisib & Fulvestrant for PIK3CA-mutated Estrogen Receptor Endometrial Cancers

    • GOG3083

      OPEN TO ACCRUAL

      Ph 3 Trial of Selinexor for Patients w/ p53 Wild Type, Advanced, or Recurrent Endometrial Carcinoma

    • GOG3104

      OPEN TO ACCRUAL

      Randomized Open Label Ph3 study of Sacituzumab Govitecan VS Phys Choice in Endometrial Cancer

    • NRGGY028

      OPEN TO ACCRUAL

      Ph1B and Randomized PhII trial of Megestrol Acetate w/ or w/o Ipatasertib in Endometrial Cancer